Mark A. Goldsmith, M.D., Ph.D.

Mark A. Goldsmith, M.D., Ph.D.

President and Chief Executive OfficeratRevolution Medicines· In proxies 2021–2025

Pay in FY2025+46% from the year before · Revolution Medicines stock +82.1% the same year

Mark A. Goldsmith, M.D., Ph.D. was paid $14.7M in FY2025 (Dec), up 46%. Revolution Medicines stock rose 82.1% that year.

Pay$100 in the stock at the end of FY20 → $201
Pay is from the Summary Compensation Table of each Revolution Medicines proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Revolution MedicinesPublic company · 5 yr
    • President and Chief Executive Officer2021 – Present · 5 yrStock in role +343%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?